


Stabilis



Fluorouracil



Noms commerciaux

Acoflut	Mexique
Adrucil	Etats Unis d'Amérique
Fivocil	Inde
Fivoflu	Inde, Malaisie
Fluorouracil	Allemagne, Arabie Saoudite, Autriche, Belgique, Brésil, Canada, Danemark, Espagne, Etats Unis d'Amérique, Finlande, Grande Bretagne, Grèce, Hongrie, Italie, Norvège, Pays bas, Pologne, Portugal, Serbie, Suisse, Turquie
Fluorouracile	France, Italie, Maroc, Tunisie
Flurablastin	Danemark, Finlande, Islande, Norvège, Suède
Fluracedyl	Belgique, Luxembourg, Malaisie, Pays bas
Flurox	Equateur, Mexique
Neoflur	Egypte
Ribofluor	Allemagne
Triosules	Argentine



Stabilité des solutions

		1,44 mg/ml	23°C		72			1501
		1,44 mg/ml	4°C		72			1501
		1,5 mg/ml	25°C		56			840
		5 mg/ml	2-8°C		91			110
		1,44 mg/ml	23°C		72			1501
		1,44 mg/ml	4°C		72			1501
		1,5 mg/ml	25°C		56			840
		0,5 & 5 mg/ml	25°C		13			39
		0,5 & 5 mg/ml	4°C		13			39
		1 & 10 mg/ml	21°C		14			1475

PVC		1 & 10 mg/ml	4°C		14			1475
PVC		1,44 mg/ml	23°C		72			1501
PVC		1,44 mg/ml	4°C		72			1501
PVC		1,5 mg/ml	25°C		56			840
PVC		10 mg/ml	4°C		30			40
PVC		5 mg/ml	2-8°C		91			110
PVC		8 mg/ml	-20°C		79			2323
PVC		8 mg/ml	5°C		28			2323
PVC		0,5 & 5 mg/ml	25°C		13			39
PVC		0,5 & 5 mg/ml	4°C		13			39
PVC		1 & 10 mg/ml	21°C		14			1475
PVC		1 & 10 mg/ml	25°C		72			842
PVC		1 & 10 mg/ml	4°C		72			842
PVC		1 & 10 mg/ml	4°C		14			1475
PVC		1,44 mg/ml	23°C		72			1501
PVC		1,44 mg/ml	4°C		72			1501
PVC		1,5 mg/ml	25°C		56			840
PVC		10 mg/ml	25°C		112			1040
PVC		10 mg/ml	4°C		30			40
PVC		10 mg/ml	5°C		112			1040
PVC		25 mg/ml	37°C		14			484
PVC		25 mg/ml	4°C		14			484
PVC		50 mg/ml	25°C		7			415
PVC		50 mg/ml	33°C		14			1475
PVC		50 mg/ml	37°C		7			415
PE		1,44 mg/ml	21-22°C		48			1520
PE		1,44 mg/ml	23°C		72			1501
PE		1,44 mg/ml	4°C		72			1501
PE		1,44 mg/ml	4°C		48			1520
PE		1,44 mg/ml	21-22°C		48			1520
PE		1,44 mg/ml	23°C		72			1501
PE		1,44 mg/ml	4°C		72			1501
PE		1,44 mg/ml	4°C		48			1520

POF	▲	7 mg/ml	21-25°C	?	17	☾		4735
POF	▲	8 mg/ml	21-25°C	?	24	☾		4735
POF	▲	9 >> 15 mg/ml	2-8°C	☀	106	☾		4868
POF	▲	9 >> 15 mg/ml	25°C	☀	24	☑		4868
EVA	▲	10 mg/ml	22°C	☀	28	☾		142
EVA	▲	10 mg/ml	25°C	☀	28	☾		844
EVA	▲	10 mg/ml	35°C	☀	28	☾		142
EVA	▲	10 mg/ml	35°C	☀	28	☾		844
EVA	▲	10 mg/ml	4°C	☀	28	☾		844
EVA	▲	15 & 45 mg/ml	25°C	☀	3	☾		33
EVA	◆	10 mg/ml	22°C	☀	28	☾		142
EVA	◆	10 mg/ml	25°C	☀	28	☾		844
EVA	◆	10 mg/ml	35°C	☀	28	☾		142
EVA	◆	10 mg/ml	35°C	☀	28	☾		844
EVA	◆	10 mg/ml	4°C	☀	28	☾		844
EVA	∅	50 mg/ml	22°C	☀	28	☾		142
EVA	∅	50 mg/ml	25°C	☀	28	☾		844
EVA	∅	50 mg/ml	33°C	☀	14	☾		1475
EVA	∅	50 mg/ml	35°C	☀	28	☾		142
EVA	∅	50 mg/ml	35°C	☀	28	☾		844
PE	▲	0,1 mg/ml	-10°C	☀	7	☾		1812
PE	▲	0,1 mg/ml	25°C	☀	7	☾		1812
PE	▲	0,1 mg/ml	40°C	☀	7	☾		1812
PE	▲	0,1 mg/ml	5°C	☀	7	☾		1812
PE	▲	12 & 40 mg/ml	25°C	☀	3	☾		33
PE	◆	12 & 40 mg/ml	25°C	☀	3	☾		33
PE	∅	25 mg/ml	2-8°C	☀	84	☾		3670
PE	∅	50 mg/ml	30°C	?	21	☾		5
PI	◆	5 & 30 mg/ml	25°C	?	60	☾		4759
PI	◆	5 & 30 mg/ml	33°C	?	7	☾		4759
PI	◆	8,3 mg/ml	5°C	☀	112	☾		1040
PI	∅	50 mg/ml	25°C	?	60	☾		4759
PI	∅	50 mg/ml	33°C	?	7	☾		4759

		25 mg/ml	25°C		21			1817
		25 mg/ml	31°C		21			1817
		25 mg/ml	4°C		14			1817
		35 mg/ml	21-25°C		28			4568
		35 mg/ml	30°C		3			4568
		44 mg/ml	21-25°C		28			4568
		44 mg/ml	30°C		3			4568
		25 mg/ml	25°C		21			1817
		25 mg/ml	31°C		21			1817
		25 mg/ml	4°C		14			1817
		50 mg/ml	25°C		21			1817
		50 mg/ml	31°C		21			1817
		50 mg/ml	37°C		56			1842



Stabilité en mélange

		1 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
		16.7 mg/ml	5-25°C		Folate sodium : 16.7 mg/ml	5		5029
		35.8 mg/ml	5-25°C		Folate sodium : 7.1 mg/ml	5		5029
		40.8 mg/ml	5-25°C		Folate sodium : 4.6 mg/ml	5		5029
		0,08 mg/ml	25°C		Palonosetron hydrochloride : 26 µg/ml	4		2009
		16.7 mg/ml	5-25°C		Folate sodium : 16.7 mg/ml	5		5029
		35.8 mg/ml	5-25°C		Folate sodium : 7.1 mg/ml	5		5029
		40.8 mg/ml	5-25°C		Folate sodium : 4.6 mg/ml	5		5029
	RL	16.7 mg/ml	5-25°C		Folate sodium : 16.7 mg/ml	5		5029
	RL	35.8 mg/ml	5-25°C		Folate sodium : 7.1 mg/ml	5		5029
	RL	40.8 mg/ml	5-25°C		Folate sodium : 4.6 mg/ml	5		5029
PVC		1 & 16 mg/ml	-20°C		Hydromorphone hydrochloride : 0,5 mg/ml	35		513
PVC		16 mg/ml	23°C		Hydromorphone hydrochloride : 0,5 mg/ml	7		513
PVC		1 mg/ml	23°C		Hydromorphone hydrochloride : 0,5 mg/ml	35		513
PVC		16 mg/ml	32°C		Hydromorphone hydrochloride : 0,5 mg/ml	3		513
PVC		1 mg/ml	32°C		Hydromorphone hydrochloride : 0,5 mg/ml	7		513

		1 & 16 mg/ml	4°C		Hydromorphone hydrochloride : 0,5 mg/ml	35		513
		16.7 mg/ml	5-25°C		Folinate sodium : 16.7 mg/ml	5		5029
		35.8 mg/ml	5-25°C		Folinate sodium : 7.1 mg/ml	5		5029
		40.8 mg/ml	5-25°C		Folinate sodium : 4.6 mg/ml	5		5029
		1 & 16 mg/ml	-20°C		Hydromorphone hydrochloride : 0,5 mg/ml	35		513
		16 mg/ml	23°C		Hydromorphone hydrochloride : 0,5 mg/ml	7		513
		1 mg/ml	23°C		Hydromorphone hydrochloride : 0,5 mg/ml	35		513
		16 mg/ml	32°C		Hydromorphone hydrochloride : 0,5 mg/ml	3		513
		1 mg/ml	32°C		Hydromorphone hydrochloride : 0,5 mg/ml	7		513
		1 & 16 mg/ml	4°C		Hydromorphone hydrochloride : 0,5 mg/ml	35		513
		16.7 mg/ml	5-25°C		Folinate sodium : 16.7 mg/ml	5		5029
		35.8 mg/ml	5-25°C		Folinate sodium : 7.1 mg/ml	5		5029
		40.8 mg/ml	5-25°C		Folinate sodium : 4.6 mg/ml	5		5029
	RL	16.7 mg/ml	5-25°C		Folinate sodium : 16.7 mg/ml	5		5029
	RL	35.8 mg/ml	5-25°C		Folinate sodium : 7.1 mg/ml	5		5029
	RL	40.8 mg/ml	5-25°C		Folinate sodium : 4.6 mg/ml	5		5029
		1 & 2 mg/ml	25°C		Mannitol : 200 mg/ml	24		411
		24 mg/ml	37°C		Heparin sodium : 960 UI/ml	7		163
		24 mg/ml	4°C		Heparin sodium : 960 UI/ml	14		163



Facteur influençant la stabilité

				1415
				301
				138
				1998



Compatibilités

			163
			413
			3474

		Fluorouracil : 16 mg/ml Allopurinol sodium : 3 mg/ml		307
		Fluorouracil : 16 mg/ml Amifostine : 10 mg/ml		3
		Fluorouracil : 16 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Fluorouracil : 16 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Fluorouracil : 16 mg/ml Aztreonam : 40 mg/ml		99
		Fluorouracil Carboplatin		3474
		Fluorouracil : 0.5 mg/ml Cefalotin sodium : 1 mg/ml		431
		Fluorouracil : 1 mg/ml Cisplatin : 0,2 mg/ml		413
		Fluorouracil Cisplatin		3578
		Fluorouracil Cisplatin		3474
		Fluorouracil : 0.25 mg/ml Cytarabine : 0.4 mg/ml		431
		Fluorouracil Cytarabine		3580
		Fluorouracil Cytarabine		3474
		Fluorouracil Daunorubicin hydrochloride		3474
		Fluorouracil Diazepam		3474
		Fluorouracil : 16 mg/ml Doripenem : 5 mg/ml		2262
		Fluorouracil : 16 mg/ml Doripenem : 5 mg/ml		2262
		Fluorouracil Doxorubicin hydrochloride		3645
		Fluorouracil : 50 mg/ml Doxorubicin hydrochloride : 2 mg/ml		763
		Fluorouracil Doxorubicin hydrochloride		3474
		Fluorouracil : 6.5 mg/ml Folinate calcium : 4 mg/ml		2181
		Fluorouracil Folinate calcium		3474
		Fluorouracil : 16 mg/ml		301
		Fluorouracil Droperidol		3474
		Fluorouracil Filgrastim		3474
		Fluorouracil : 50 mg/ml Gallium nitrate : 1 mg/ml		91

		Fluorouracil Gallium nitrate		3474
		Fluorouracil : 16 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Fluorouracil : 16 mg/ml Granisetron hydrochloride : 0,05 mg/ml		49
		Fluorouracil		3474
		Fluorouracil : 1 & 16 mg/ml Fentanyl citrate : 12.5 µg/ml		514
		Fluorouracil : 16 mg/ml Filgrastim : 30 µg/ml		244
		Fluorouracil : 50 mg/ml Folinate calcium : 30.8 mg/ml		2130
		Fluorouracil : 16.67 >> 46.15 mg/ml Folinate calcium : 1.54 >> 13.33 mg/ml		155
		Fluorouracil : 6.5 mg/ml Folinate calcium : 4 mg/ml		2181
		Fluorouracil : 50 mg/ml Folinate calcium : 30.8 mg/ml		2181
		Fluorouracil : 16 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Fluorouracil : 24 mg/ml Heparin sodium : 960 UI/ml		163
		Fluorouracil : 1 mg/ml		1325
		Fluorouracil : 16.67 >> 46.15 mg/ml Folinate calcium : 1.54 >> 13.33 mg/ml		155
		Fluorouracil : < 12.5 mg/ml		3948
		Fluorouracil Epirubicin hydrochloride		3474
		Fluorouracil : 1 & 16 mg/ml Fentanyl citrate : 12.5 µg/ml		514
		Fluorouracil : 50 mg/ml Folinate calcium : 30.8 mg/ml		2181
		Fluorouracil : 50 mg/ml Furosemide : 10 mg/ml		763
		Fluorouracil : 50 mg/ml Heparin sodium : 1 UI/ml		1228
		Fluorouracil : 50 mg/ml Heparin sodium : 1 UI/ml	RL	1228
		Fluorouracil : 50 mg/ml Heparin sodium : 1 UI/ml		1228
		Fluorouracil : 0,8 mg/ml Heparin sodium : 5 UI/ml		156
		Fluorouracil : 16 mg/ml		1415
		Fluorouracil		3474
		Fluorouracil : 2 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Fluorouracil : 25 & 50 mg/ml		3948
		Fluorouracil : 25 & 50 mg/ml		3948

		Fluorouracil : 16 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Fluorouracil : 50 mg/ml Droperidol : 2,5 mg/ml		763
		Fluorouracil : 16 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Fluorouracil : 16 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Fluorouracil : 6.5 mg/ml Folinate calcium : 30.8 mg/ml		2130
		Fluorouracil : 50 mg/ml Folinate calcium : 10 mg/ml		763
		Fluorouracil Folinate sodium		5029
		Fluorouracil : 0,8 mg/ml Heparin sodium : 5 UI/ml		156
		Fluorouracil : 50 mg/ml Heparin sodium : 1000 UI/ml		763
		Fluorouracil : 50 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Fluorouracil : 50 mg/ml Hydrocortisone sodium succinate : 1 mg/ml	RL	1228
		Fluorouracil : 50 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		1228
		Fluorouracil : 1 & 16 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		513
		Fluorouracil : 1 & 16 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		513
		Fluorouracil Idarubicin hydrochloride		3474
		Fluorouracil : 25 mg/ml Irinotecan : 2 mg/ml		3873
		Fluorouracil : 16 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Fluorouracil : 50 mg/ml Levofolinate calcium : 15.4 mg/ml		2130
		Fluorouracil : 16.67 >> 46.15 mg/ml Levofolinate calcium : 1.54 >> 13.33 mg/ml		155
		Fluorouracil : 10,8 mg/ml Levofolinate calcium : 1,8 mg/ml		3369
		Fluorouracil : 6.5 mg/ml Levofolinate calcium : 4 mg/ml		2181
		Fluorouracil : 50 mg/ml Levofolinate calcium : 15.4 mg/ml		2181
		Fluorouracil : 6.5 mg/ml Levofolinate calcium : 15.4 mg/ml		2130
		Fluorouracil : 16.67 >> 46.15 mg/ml Levofolinate calcium : 1.54 >> 13.33 mg/ml		155
		Fluorouracil : 6.5 mg/ml Levofolinate calcium : 4 mg/ml		2181
		Fluorouracil : 10,8 mg/ml Levofolinate calcium : 1,8 mg/ml		3369

	Fluorouracil : 50 mg/ml Levofolinate calcium : 15.4 mg/ml		2181
	Fluorouracil : 16 mg/ml Linezolid : 2 mg/ml		1925
	Fluorouracil Methotrexate sodium		3474
	Fluorouracil Methotrexate sodium		3637
	Fluorouracil Metoclopramide hydrochloride		3474
	Fluorouracil Morphine hydrochloride		3474
	Fluorouracil : 1 & 16 mg/ml Morphine sulfate : 1 mg/ml		513
	Fluorouracil Morphine sulfate		3474
	Fluorouracil Morphine sulfate		3531
	Fluorouracil Morphine tartrate		3474
	Fluorouracil : < 0,8 mg/ml Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml		3574
	Fluorouracil Ondansetron hydrochloride		3474
	Fluorouracil : > 0,8 mg/ml Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml		3574
	Fluorouracil Oxaliplatin		3634
	Fluorouracil : 16 mg/ml Pemetrexed disodium : 20 mg/ml		1953
	Fluorouracil : 50 mg/ml Potassium chloride : 40 mEq/l	RL	1228
	Fluorouracil : 50 mg/ml Potassium chloride : 40 mEq/l		1228
	Fluorouracil : 50 mg/ml Potassium chloride : 40 mEq/l		1228
	Fluorouracil : 16 mg/ml Propofol : 10 mg/ml		300
	Fluorouracil Vinorelbine tartrate		3474
	Fluorouracil		3474
	Fluorouracil : 1 & 2 mg/ml Mannitol : 200 mg/ml		411
	Fluorouracil : 16 mg/ml Melphalan : 0.1 mg/ml		169
	Fluorouracil : 50 mg/ml Methotrexate sodium : 25 mg/ml		763
	Fluorouracil : 0.25 mg/ml Methotrexate sodium : 0.2 mg/ml		431
	Fluorouracil : 2,5 mg/ml Metoclopramide hydrochloride : 0,1 mg/ml		153

		Fluorouracil : 50 mg/ml Metoclopramide hydrochloride : 5 mg/ml		763
		Fluorouracil Morphine hydrochloride		5069
		Fluorouracil : 1 & 16 mg/ml Morphine sulfate : 1 mg/ml		513
		Fluorouracil : 16 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Fluorouracil : 16 mg/ml Paclitaxel : 1.2 mg/ml		85
		Fluorouracil : 16 mg/ml Palonosetron hydrochloride : 50 µg/ml		2009
		Fluorouracil : 16 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Fluorouracil : 16 mg/ml Sargramostim : 10 µg/ml		335
		Fluorouracil : 16 mg/ml Teniposide : 0.1 mg/ml		905
		Fluorouracil : 16 mg/ml Thiotepa : 1 mg/ml		249
		Fluorouracil : 50 mg/ml Topotecan : 0.056 mg/ml		1026
		Fluorouracil : 50 mg/ml Topotecan : 0.056 mg/ml		1026
		Fluorouracil : 50 mg/ml Vinblastine sulfate : 1 mg/ml		763
		Fluorouracil : 50 mg/ml Vincristine sulfate : 1 mg/ml		763
		Fluorouracil : 0.010 mg/ml Vincristine sulfate : 0.004 mg/ml		431
		Fluorouracil : 16 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Fluorouracil : < 12.5 mg/ml		3948



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.

5	Revue	Stiles ML, Allen LV Jr, Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
33	Revue	Baud-Camus F, Crauste-Manciet S, Klein E, Richard L, Brossard D. Stability of fluorouracil in polypropylene syringes and ethylene vinyl acetate infusion-pump reservoirs. Am J Health-Syst Pharm 1996 ; 53: 1457-1458.
39	Revue	Farhang-Asnafi S, Callaert S, Barre J, Tillement JP, Thebault A. Influence of intravenous admixtures on the stability of the new solution of 5-fluorouracil. J Pharm Clin 1997 ; 16: 45-48.
40	Revue	Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. Pharm Sci Communications 1994 ; 4: 97-101.
49	Revue	Trissel LA, Martinez JF. Compatibility of granisetron hydrochloride with selected alkaline drugs. Am J Health-Syst Pharm 1995 ; 52: 208.
57	Revue	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Revue	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
110	Revue	Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM. Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers. Int J Pharm 1989 ; 54: 181-189.
138	Revue	Corbrion V, Crauste-Manciet S, Allain P, Brossard D. Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint. Am J Health-Syst Pharm 1997 ; 54: 1845-1848.
142	Revue	Rochard EB, Barthes DMC, Courtois PY. Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 619-623.
153	Revue	Wang DP, Chang LC, Lee DK. Stability of fluorouracil-metoclopramide hydrochloride admixture. Am J Health-Syst Pharm 1995 ; 52: 98-99.

155	Revue	Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health-Syst Pharm 1995 ; 52: 710-715.
156	Revue	Barberi-Hayob M, Merlin JL, Vigneron M, Conroy T. Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions. Anticancer Drugs 1995 ; 6: 163-164.
163	Revue	Sewell GJ, Allsopp M, Collinson MP, Tyrrell C, Prentice AJ, Copplestone JA. Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens. J Clin Pharm Ther 1994 ; 19: 127-133.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
411	Revue	Woloschuk DMM, Wermeling JR, Pruemer JM. Stability and compatibility of fluorouracil and mannitol during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 2158-2160.
413	Revue	Stewart CF, Fleming RA. Compatibility of cisplatin and fluorouracil in 0.9% sodium chloride injection. Am J Hosp Pharm 1990 ; 47: 1373-1377.
415	Revue	Stiles ML, Allen LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. Am J Hosp Pharm 1989 ; 46: 2036-2040.

431	Revue	McRae MP, King JC. Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 1975 ; 33: 1010-1013.
484	Revue	Northcott M, Allsopp MA, Powell H, Sewell GJ. The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged "in use" conditions. J Clin Pharm Ther 1991 ; 16: 123-129.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
513	Revue	Xu QA, Trissel LA, Martinez JF. Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride. Ann Pharmacotherapy 1996 ; 30: 756-761.
514	Revue	Xu QA, Trissel LA, Martinez JF. Rapid loss of fentanyl citrate admixed with fluorouracil in polyvinyl chloride containers. Ann Pharmacotherapy 1997 ; 31: 297-302.
763	Revue	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
840	Revue	Biondi L, Nairn JG. Stability of 5-fluorouracil and flucytosine in parenteral solutions. Can J Hosp Pharm 1986 ; 39: 60-66.
842	Revue	Pinguet F, Favre G, Canal P, Pujol A, Soula G. Stability of 5-fluorouracil to heat and light. J Pharm Clin 1990 ; 9: 155-158.
844	Revue	Rochard E, Chapelle G, Bouquet S, Barthes D, Courtois PH. Stability of fluorouracil and cytarabine in ethylvinylacetate containers. J Pharm Clin 1989 ; 9: 31-35.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1026	Revue	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1040	Revue	Quebbeman EJ, Hamid AAR, Hoffman NE, Ausman RK. Stability of fluorouracil in plastic containers used for continuous infusion at home. Am J Hosp Pharm 1984 ; 41: 1153-1156.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
1325	Revue	Hardin TC, Clibon U, Page CP, Cruz AB. Compatibility of 5-fluorouracil and total nutrition solutions. JPEN 1982 ; 6: 163-165.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.

1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1475	Revue	Martel P, Petit I, Pinguet F, Poujol S, Astre C, Fabbro M. Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. J Pharm Biomed Anal 1996 ; 14: 395-399.
1501	Revue	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Laboratoire	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1812	Revue	Fuhrman LC, Godwin DA, Davis RA. Stability of 5-fluorouracil in an extemporaneously compounded ophthalmic solution. Int J Pharm Compound 2000 ; 4, 4: 320-323.
1817	Revue	Roberts S, Sewell GJ. Stability and compatibility of 5-fluorouracil infusions in the Braun Easypump®. J Oncol Pharm Practice 2003 ; 9: 109-112.
1842	Revue	Sadjack A, Wintersteiger R. Compatibility of morphin, baclofen, floxuridine and fluorouracil in an implantable infusion pump. Arzneimittel Forschung 1995 ; 45: 93-98.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
1998	Revue	Allwood MC. Fluorouracil precipitate. Am J Health-Syst Pharm 1998 55: 1315-1316.
2009	Revue	Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 2005, 9, 4: 320-322.
2130	Revue	Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. Stabilité du mélange 5-fluoro-uracil-acide folinique : influence des concentrations, du contenant et de la forme de l'acide folinique. Bull Cancer 1999 ; 86, 11: 946-954.
2181	Revue	Milano G, Renée N. Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. Bull Cancer 1995 ; 82: 189-195.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.

2323	Revue	Galanti L, Lebitasy M.P, Hecq J.D, Cadrobbi J, Vanbeckbergen D, Jamart J. Long-Term Stability of 5-Fluorouracil in 0.9% Sodium Chloride after Freezing, Microwave Thawing, and Refrigeration Can J Hosp Pharm 2009 ; 62, 1
3369	Laboratoire	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3531	Laboratoire	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3574	Laboratoire	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3578	Laboratoire	Cisplatine - Summary of Product Characteristics Accord Healthcare 2011
3580	Laboratoire	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3634	Laboratoire	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3637	Laboratoire	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hamel Pharmaceuticals 2014
3645	Laboratoire	Doxorubicin - Summary of Product Characteristics Accord Healthcare 2014
3670	Revue	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3873	Revue	Tan X, Hu J. Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 2016 ; 73:755.
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
4568	Revue	Closset M, Onorati S, Colsoul M.L, Goderniaux N, Bihin B, Jamart J, Soumoy L, Hecq J.D, Odou P, Galanti L. Long-term physico-chemical stability of 5-fluorouracil at standardised rounded doses (SRD) in MyFuser® portable infusion pump. Journal of Chemotherapy 2021
4735	Revue	Closset M, Onorati S, Colsoul M-L, Goderniaux N, Bihin B, Jamart J, Soumoy L, Hecq J-D, Odou P, Galanti L. Long-term physicochemical stability of 5-fluorouracil at selected standardised rounded doses in polyolefin bags. J Oncol Pharm Practice 2023 ;29,8:1878 - 1883
4759	Poster	Ma NH, Charbonneau LF, Law S, Walker S. Stability of 5-fluorouracil at 4°C, 25°C, and 33°C stored in NiproSureFuser+ Ambulatory Balloon Infusers. Sunnybrook Health Science Centre 2023
4868	Poster	Bataillard T, Lethier L, Ben Mahi M, Peudepiece C, Chatelain J, Fagnoni-Légat C, André C, Guillaume Y. Etude de la stabilité physico-chimique de solutions de 5-fluorouracil diluées en poches polyoléfine a des concentrations comprises entre 9 et 15 mg/ml. CSH (SNPHPU) Congress sept 2024 2024
5029	Laboratoire	VoriNa 25 mg/ml solution injectable - Résumé des caractéristiques du produit. Teva Pharma Belgium S.A. 2020
5069	Laboratoire	MORPHINE (CHLORHYDRATE) AGUETTANT 10 mg/mL, solution injectable - Résumé des caractéristiques du produit. LABORATOIRE AGUETTANT 2024



Dictionnaire

 Anticancéreux	 injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Chlorure de sodium 0,9%	 A l'abri de la lumière
 Heure	 Avec ou sans lumière
 Jour	 Glucose 5%
 Polyvinyl chlorure	 Lumière
 Aucun	 Polyéthylène
 Non précisée	 Polyolefine
 Ethylène vinyl acétate	 Seringue polypropylène
 Elastomère en polyisoprène	 Elastomère en silicone
 Non précisé	 Stabilité en mélange
 Solvant	 Molécule
RL Ringer lactate	 Facteur influençant la stabilité
 Nutrition parentérale (mélange ternaire)	 Provoque
 Dégradation	 Nutrition parentérale (mélange binaire)
 Précipitation	 Compatibilités
 Instabilité chimique	 Incompatible
 Compatible	 Précipitation immédiate
 Incompatibilité non précisée	 Turbidité immédiate
 Précipitation en 1 heure	 Précipitation en 24 heures
 Eau pour préparation injectable	 Précipitation en 15 minutes
 Précipitation en 4 heures	 Voie d'administration
 Perfusion intraveineuse	 Perfusion continue
 Intraartérielle	 Intravésicale
 Intrapéritonéale	 Intravitréenne



Sous conjonctivale



Bibliographie



Dictionnaire